Your browser doesn't support javascript.
loading
COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
Klupsch, Kristina; Baeriswyl, Vanessa; Scholz, Roland; Dannenberg, Joana; Santimaria, Roger; Senn, David; Kage, Elena; Zumsteg, Adrian; Attinger-Toller, Isabella; von der Bey, Ulrike; König-Friedrich, Susann; Dupuy, Fanny; Lembke, Wibke; Albani, Clara; Wendelspiess, Severin; Dinkel, Lucijana; Saro, Dorina; Hepler, Robert W; Laszlo, George S; Gudgeon, Chelsea J; Bertschinger, Julian; Brack, Simon; Walter, Roland B.
Afiliação
  • Klupsch K; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Baeriswyl V; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Scholz R; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Dannenberg J; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Santimaria R; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Senn D; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Kage E; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Zumsteg A; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Attinger-Toller I; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • von der Bey U; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • König-Friedrich S; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Dupuy F; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Lembke W; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Albani C; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Wendelspiess S; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Dinkel L; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Saro D; Janssen R&D, Spring House, PA, USA.
  • Hepler RW; Janssen R&D, Spring House, PA, USA.
  • Laszlo GS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Bertschinger J; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland.
  • Brack S; Covagen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, Schlieren, Switzerland. sbrack@ITS.JNJ.com.
  • Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. rwalter@fredhutch.org.
Leukemia ; 33(3): 805-808, 2019 03.
Article em En | MEDLINE | ID: mdl-30206306

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Imunoglobulina G / Leucemia Mieloide Aguda / Complexo CD3 / Anticorpos Biespecíficos / Lectina 3 Semelhante a Ig de Ligação ao Ácido Siálico Limite: Animals / Female / Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Imunoglobulina G / Leucemia Mieloide Aguda / Complexo CD3 / Anticorpos Biespecíficos / Lectina 3 Semelhante a Ig de Ligação ao Ácido Siálico Limite: Animals / Female / Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça